A second-wave psychedelics company

Tidal Care Inc. P.TDL

Healthcare Biotechnology

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the psychedelic therapeutics industry, as well as a force for new avenues of research and product development. The company will accomplish this through a two-pronged approach; Academic research partnerships, and a translational scale up and manufacturing through a high-compliance licensed lab facility.

< Previous

Next >

"By fostering strong connections and research partnerships with licensed post-secondary institutions across Canada, Tidal can drive a significantly level of early-stage research and product development at low cost while simultaneously helping to train the next generation of scientists emerging into the psychedelic therapeutics space. The products, methods, and other intellectual property developed through these partnerships will be leveraged towards the translation from bench side research to clinical drug development utilizing our state-of-the-art laboratory. By ensuring a high-level of GMP or higher compliance for drug manufacturing, Tidal will be able to serve Canada as well as other jurisdictions as they progress down the regulatory path. By doing so, Tidal will remain at the forefront of research in this field, with a mechanism to translate promising discoveries efficiently into high-compliance clinical products."

Dylan Beesley - VP, Operations & Business Development

Current News (:TDL)

No current news is available.

View More News ››

"Tidal Care Inc. is excited to announce a research and product-development partnership with the University of Guelph. Dr. Max Jones and Dr. Gale Bozzo, professors in the Ontario Agricultural College’s Department of Plant Agriculture, have obtained a Health Canada dealer’s licence that allows them and their teams to cultivate mushrooms that are known to produce psilocybin and other compounds. Tidal will be working in conjunction with Drs. Jones and Bozzo to engage in vital early-phase mushroom research, validation, optimization, and analysis that will be of significant benefit to Tidal and the psychedelics industry as a whole."

Shawn Brown, CEO

Opinion & Analysis (:TDL)

No current opinion is available.

View More Opinion ››

"By joining Tidal Care Inc, you will be a part of a movement to change our approach to mental health and personal wellness. This is a bigger problem than any one of us can tackle alone but together, we can turn the Tide."

Shawn Brown, CEO

Bullboard Posts (:TDL)

Welcome

This is a new forum for Tidal Care Inc.

concierge - December 22, 2023

View more Bullboard ››

Connect with Tidal Care Inc.

PARTNERS CONTACT COMPANY UPDATES

Investor Presentation

We, are Tidal.

Tidal aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the psychedelic therapeutics industry, as well as a force for new avenues of research and product development. We will accomplish this through a two-pronged approach; Academic research partnerships, and translational scale up and manufacturing through a high-compliance licensed lab facility.

Contact Us

GLOBAL HEADQUARTERS
Nisku, AB, Canada

CONTACT
info@tidalcare.com

Become a member today, It's free!

Sign In

Send my password